CROWN BIOSCIENCE

# OrganoidXplore™

Unlock the Future of Cancer Research with Crown Bioscience's Organoid Panel Screening Service

A JSR Life Sciences Company

FACTSHEET

## Exploring Drug Efficacy with Organoid Models

This screening service enables the thorough examination of a wide range of cancer models, anchored by a comprehensive library of Patient-Derived Organoid (PDO) and Patient-Derived Xenograft Organoid (PDXO) models with detailed mutational landscapes. It offers a systematic approach to quantifying drug effects on both tumor and normal tissue organoids, enhancing the understanding of therapeutic impacts.

- Fast-track your oncology drug development with results from 50 models
- Identify your lead compound(s), stratify patients into responders, partial responders, and non-responders or preselect models for follow up studies *in vitro/in vivo*.

### Leverage Diverse Model Selection

**Quantify efficacy across organoids with specific mutations and diverse genetic backgrounds.**

- Measure tumor drug response in both tumor and normal organoids
- Explore new the indications with validated targets
- Benefit from inclusion of 9 normal models, including 6 matched normal/disease pairs for comprehensive analysis
- Access 50 well-characterized PDO and PDXO models for enhanced precision
- Representing clinically relevant mutational profiles, including KRAS, BRAF, BRCA 1 and 2, and EGFR

### Uncover Viable Targets With Confidence

**Rely on rigorous validation and quality assurance procedures to ensure the accuracy and trustworthiness of your data.**

- Organoid quality assurance: SNP verified and mycoplasma tested
- Quantify cell viability and explore potential drug combinations
- Evaluated with four benchmark standard of care agents: Cisplatin, Gemcitabine, Paclitaxel, and AMG510
- Assay performance validated by inclusion of chemotherapeutic agent and vehicle controls on each plate

### Select the Panel That Best Suits Your Needs

**Explore new indications and test efficacy in our** Organoid**Xplore™ panels.**







**Full Panel** — 50 models — 7 indications

**KRAS Panel** — 25 models — 4 indications

**RNA seq, WES and SoC data available**
**Most models available as PDX for follow-up studies**

## Observe Streamlined Precision in Action

**Ensure accuracy and reproducibility across runs with a semi-automated workflow that uses liquid handlers.**




**Day 0: Seeding using assay-ready organoids**

**Day 1: Compound addition**

**Day 6: CellTiterGlo® read-out**




- Agents tested at 9 concentrations on the preferred panel
- 5-day incubation time with compounds for timely results
- Benefit from vehicle and reference controls for reliable comparisons
- Optional: conduct drug combination studies for enhanced therapeutic potential
- Receive a comprehensive customer report containing 9-point dose-response curve graphs, $IC_{50}$s, study design and control performance

## Get in touch


**Sales**
**US:** +1 858 622 2900
**UK:** +44 870 242 2900
busdev@crownbio.com
www.crownbio.com

**Science**
consultation@crownbio.com